373 related articles for article (PubMed ID: 25523367)
1. Therapeutic monoclonal antibodies and the need for targeted pharmacovigilance in India.
Kalaivani M; Singh A; Kalaiselvan V
MAbs; 2015; 7(1):276-80. PubMed ID: 25523367
[TBL] [Abstract][Full Text] [Related]
2. Drug safety alerts of pharmacovigilance programme of India: A scope for targeted spontaneous reporting in India.
Thota P; Thota A; Medhi B; Sidhu S; Kumar P; Selvan VK; Singh GN
Perspect Clin Res; 2018; 9(1):51-55. PubMed ID: 29430420
[TBL] [Abstract][Full Text] [Related]
3. Cefixime-associated acute generalized exanthematous pustulosis: Rare cases in India.
Kumar V; Kalaiselvan V; Kumar AP; Saurabh A; Thota P; Sidhu S; Medhi B
Indian J Pharmacol; 2018; 50(4):204-207. PubMed ID: 30505057
[TBL] [Abstract][Full Text] [Related]
4. Development of Pharmacovigilance System in India and Paradigm of Pharmacovigilance Research: An Overview.
Singh P; Vaishnav Y; Verma S
Curr Drug Saf; 2023; 18(4):448-464. PubMed ID: 36200243
[TBL] [Abstract][Full Text] [Related]
5. Adverse event reporting tools and regulatory measures in India through outcome of Pharmacovigilance Programme of India.
Prakash J; Sachdeva R; Shrivastava TP; Jayachandran CV; Sahu A
Indian J Pharmacol; 2021; 53(2):143-152. PubMed ID: 34100398
[TBL] [Abstract][Full Text] [Related]
6. Pharmacovigilance in India: Present Scenario and Future Challenges.
Kalaiselvan V; Srivastava S; Singh A; Gupta SK
Drug Saf; 2019 Mar; 42(3):339-346. PubMed ID: 30269244
[TBL] [Abstract][Full Text] [Related]
7. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
Tandon VR; Mahajan V; Khajuria V; Gillani Z
Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
[TBL] [Abstract][Full Text] [Related]
8. A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
Ogar CK; Abiola A; Yuah D; Ibrahim A; Oreagba IA; Amadi EC; Adeyeye MC; Oshikoya KA
Pharmaceut Med; 2019 Apr; 33(2):145-157. PubMed ID: 31933250
[TBL] [Abstract][Full Text] [Related]
9. Adverse drug reactions at adverse drug reaction monitoring center in Raipur: Analysis of spontaneous reports during 1 year.
Singh P; Agrawal M; Hishikar R; Joshi U; Maheshwari B; Halwai A
Indian J Pharmacol; 2017; 49(6):432-437. PubMed ID: 29674797
[TBL] [Abstract][Full Text] [Related]
10. "ADR PvPI" Android mobile app: Report adverse drug reaction at any time anywhere in India.
Prakash J; Joshi K; Malik D; Mishra O; Sachan A; Kumar B; Bhushan S; Kalaiselvan V; Singh GN
Indian J Pharmacol; 2019; 51(4):236-242. PubMed ID: 31571709
[TBL] [Abstract][Full Text] [Related]
11. Pharmacovigilance Programme of India: Recent developments and future perspectives.
Kalaiselvan V; Thota P; Singh GN
Indian J Pharmacol; 2016; 48(6):624-628. PubMed ID: 28066097
[TBL] [Abstract][Full Text] [Related]
12. Adverse reactions to contrast media: an analysis of spontaneous reports in the database of the pharmacovigilance programme of India.
Kalaiselvan V; Sharma S; Singh GN
Drug Saf; 2014 Sep; 37(9):703-10. PubMed ID: 25085041
[TBL] [Abstract][Full Text] [Related]
13. EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies.
Francescon S; Fornasier G; Baldo P
Int J Clin Pharm; 2018 Aug; 40(4):778-782. PubMed ID: 30094558
[TBL] [Abstract][Full Text] [Related]
14. A national approach to pharmacovigilance: The case of India as a growing hub of global clinical trials.
Dylan Fernandes S; Anoop NV; Castelino LJ; Narayana Charyulu R
Res Social Adm Pharm; 2019 Jan; 15(1):109-113. PubMed ID: 29602659
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics of adverse events associated with therapeutic monoclonal antibodies in Korea.
Sim DW; Park KH; Park HJ; Son YW; Lee SC; Park JW; Lee JH
Pharmacoepidemiol Drug Saf; 2016 Nov; 25(11):1279-1286. PubMed ID: 27364925
[TBL] [Abstract][Full Text] [Related]
16. Profile of adverse drug reaction reports in South Africa: An analysis of VigiBase® for the year 2017.
Steyn H
S Afr Med J; 2023 Jun; 113(6):26-33. PubMed ID: 37278262
[TBL] [Abstract][Full Text] [Related]
17. Status of documentation grading and completeness score for Indian individual case safety reports.
Vivekanandan K; Rishi K; Prasad T; Arunabh T; Singh GN
Indian J Pharmacol; 2015; 47(3):325-7. PubMed ID: 26069373
[TBL] [Abstract][Full Text] [Related]
18. Statistical Signal Process in R Language in the Pharmacovigilance Programme of India.
Kumar A; Ahuja J; Shrivastava TP; Kumar V; Kalaiselvan V
Ther Innov Regul Sci; 2018 May; 52(3):329-333. PubMed ID: 29714534
[TBL] [Abstract][Full Text] [Related]
19. An observational study to compare the contents and quality of information furnished in CDSCO ADR reporting form, yellow card, medwatch and blue form by the healthcare professionals.
Rehan HS; Chopra D; Holani SN; Mishra R
Int J Risk Saf Med; 2014; 26(1):1-8. PubMed ID: 24796346
[TBL] [Abstract][Full Text] [Related]
20. Using real-world healthcare data for pharmacovigilance signal detection - the experience of the EU-ADR project.
Patadia VK; Coloma P; Schuemie MJ; Herings R; Gini R; Mazzaglia G; Picelli G; Fornari C; Pedersen L; van der Lei J; Sturkenboom M; Trifirò G;
Expert Rev Clin Pharmacol; 2015 Jan; 8(1):95-102. PubMed ID: 25487079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
